Deferasirox
Deferasirox (ICL 670) is an orally available iron chelator used for the management of transfusional iron overload[1][2][3].
Product Specifications
CAS Number
[201530-41-8]
Product Name Alternative
ICL 670
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Bacterial; Ferroptosis
Type
Reference compound
Related Pathways
Anti-infection; Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Deferasirox.html
Purity
99.86
Solubility
DMSO : ≥ 100 mg/mL
Smiles
O=C(O)C1=CC=C(N2N=C(C3=CC=CC=C3O)N=C2C4=CC=CC=C4O)C=C1
Molecular Formula
C21H15N3O4
Molecular Weight
373.36
Precautions
H302, H315, H319, H335
References & Citations
[1]Sobbe A, et al. Inconsistent hepatic antifibrotic effects with the iron chelator deferasirox. J Gastroenterol Hepatol. 2015 Mar;30 (3) :638-45.|[2]Kim JL, et al. The oral iron chelator deferasirox induces apoptosis in myeloid leukemia cells by targetingcaspase. Acta Haematol. 2011;126 (4) :241-5.|[3]Lee DH, et al. Deferasirox shows in vitro and in vivo antileukemic effects on murine leukemic cell lines regardless of iron status. Exp Hematol. 2013 Jun;41 (6) :539-46.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
